BioSpace News Archive

Today, the U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in a deadly form of metastatic non-small cell lung cancer (NSCLC).

Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET, Thursday, August 13, 2020 to report its second quarter 2020 financial results and discuss recent business highlights. To access the live conference call, please dial 833-528-0605 (domestic) or 830-22

Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has completed its previously announced offering of $450 million in aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028 (the “Notes”). The Notes are fully and unconditionally guaranteed on a senior unsecured basis by all of the Company’s direct and indirect subsidiaries that guarantee debt under its credit facilities. The Company has used the

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the pricing of an underwritten offering of $1.250 billion aggregate principal amount of senior unsecured notes due 2030 (the “2030 notes”) and $750 million aggregate principal amount of senior unsecured notes due 2050 (the “2050 notes” and, together with the 2030 not

Mirum Pharmaceuticals to Present at the Canaccord Genuity 40 th Annual Growth Conference

Cutera, Inc. (NASDAQ: CUTR ) (“Cutera” or the “Company”), a leading provider of energy-based aesthetic systems for practitioners worldwide, today announced that Dave Mowry, Chief Executive Officer, will present at the 40 th Annual Canaccord Genuity Growth Conference at 3:00 p.m. ET on Thursday, August 13, 2020. A live webcast of the presentation will be accessible through the “Investors” section of the Company’s w

Veracyte, Inc. announced the closing of its public offering of 6,900,000 shares of common stock, including 900,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $30.00 per share.

- Akorn, Inc. (The OTC Pink Market: AKRXQ), a leading specialty pharmaceutical company, today announced its financial results for the second quarter of 2020. Second Quarter 2020 Results and Recent Developments Net revenue was $120 million, down $58 million, 32% from the prior year quarter Net loss was $69 million, compared to $112 million loss in the prior year quarter Adjusted EBITDA was $(2) million, compared to $36 million in the pr

Flexion Therapeutics, Inc. announced equity inducement grants to two new employees consisting of 25,315 restricted stock units.

Assembly Biosciences, Inc. announced grants of stock options to two new employees to purchase an aggregate of 13,000 shares of the Company’s common stock with an exercise price of $23.08 per share, the closing price of Assembly’s common stock on August 3, 2020.